PARPis after PARPis in patients with recurrent epithelial ovarian cancer: a single institutional experience
Patients with PARPis resistant recurrent EOC may derive benefit from PARPis re-treatment, especially for those with complete response to the last chemotherapy. Patients with BRCA1/2 mutation were more likely to benefit from PARPis retreatment than those with wild-type. Anemia and thrombocytopenia were more common in PARPis retreatment patients. A small proportion of patients had a longer benefit from PARPis retreatment than from previous PARPis treatment.
Authors
- Hongwen Yao (ORCID: https://orcid.org/0000-0002-3749-9402)
- Lingying Wu (ORCID: https://orcid.org/0000-0003-3153-7786)
- Ning Li (ORCID: https://orcid.org/0000-0002-2688-4866)
- Tonghui Wang (ORCID: https://orcid.org/0000-0003-3002-5092)
- Hua Yuan (ORCID: https://orcid.org/0000-0002-9213-2988)
Institutions
- Capital Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- National Cancer Center (US)
Publication Details
- Journal
- Journal of Ovarian Research
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1186/s13048-025-01786-0
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chinese Academy of Medical Sciences